EML4 and lung cancer: Equally striking has been the rapid development of targeted therapies compared to the timeline for cytotoxic therapies, best exemplified by the development of ALK inhibitors for lung cancer, which took less than 5 years from initial identification of the EML4-ALK rearrangement as a molecular biomarker to clinical approval of the drug.